StratDeck

Two stocks in Healthcare

CVS Health vs Pfizer: profit, growth, debt and price compared

Pfizer is stronger on 4 of 7 figures: profit margin, debt, dividend and price trend. CVS Health is stronger on 3: sales growth, price for its expected profit and analysts' view.

Figures as of 18 November 2026SEC EDGARYahoo Finance

Save both stocks to your watchlist and revisit their latest fundamentals.

CVS Health and Pfizer side by side
CVS HealthCVSPfizerPFE
Net margin2.6%Stronger: 6.3%
Revenue growth, past yearStronger: +5.37%−0.43%
Debt to equity93.3%Stronger: 71.0%
Forward P/EStronger: 9.3×9.5×
Dividend yield3.27%Stronger: 6.13%
AnalystsStronger: Strong buy · 26Buy · 26
From its 200-day average−7.3%Stronger: +6.1%

Share price over the past year

  • CVS Health+4.4%
  • Pfizer+10.3%

18 Nov 202518 Nov 2026

CVS Health or Pfizer: which is stronger?

  • PFE

    Which is more profitable?

    Pfizer keeps more of each sale as profit: 6.3% against 2.6%.

  • CVS

    Which is growing its sales faster?

    CVS Health is growing its sales faster: +5.37% over the past year, against −0.43%.

  • PFE

    Which has borrowed less?

    Pfizer has borrowed less: its debt is 71.0% of what its shareholders own, against 93.3% for CVS Health.

  • CVS

    Which costs less for the profit it is expected to make?

    CVS Health costs less for the profit it is expected to make: 9.3× its forward earnings, against 9.5×.

  • PFE

    Which pays more in dividends?

    Pfizer pays more back in dividends for what a share costs: 6.13% a year, against 3.27%.

  • CVS

    Which do analysts rate higher?

    Analysts are warmer on CVS Health: Strong buy, against Buy for Pfizer.

  • PFE

    Which is in the stronger price trend?

    Pfizer's price is in the stronger trend: 6.1% above its 200-day average, against 7.3% below.

What each company does

CVSCVS Health

CVS Health Corporation provides health solutions in the United States.

Reports results on 9 February 2027

PFEPfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Reports results on 2 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.